Epix chief business officer resigns
Biopharmaceutical development firm Epix Pharmaceuticals reported that Chen Schor has resigned his position as chief business officer, effective March 23, to pursue other opportunities.
Sheila DeWitt, PhD, Epix' former head of business development and current vice president (VP) of discovery and manufacturing, will lead its business development efforts going forward, the company said.
"We thank Chen for his contributions, particularly the roles he played as we established our collaborations with Amgen, GlaxoSmithKline and the Cystic Fibrosis Foundation," said Elkan Gamzu, PhD, interim CEO of Epix. "While Sheila will continue to transition into her expanded role, to date she has already led many Vasovist-related activities, including the worldwide technology transfer of rights to Epix as well as activities in support of our efforts to monetize Vasovist."
The Lexington, Mass.-based Epix said that DeWitt joined the management team of Epix in 2005 as the VP of business development and strategic planning and transitioned to the role of VP of discovery and manufacturing in 2007. As VP of business development and strategic planning, DeWitt played an integral role in the merger with Predix Pharmaceuticals.
Previously, DeWitt served in a variety of other R&D and business development roles including, vice president portfolio development and business unit head for strategic alliances and discovery at ArQule, business unit head for Chip-Based Discovery at Orchid Biosciences, founder and VP for Diversomer Technologies and a variety of scientific positions at Parke-Davis (now Pfizer).
Sheila DeWitt, PhD, Epix' former head of business development and current vice president (VP) of discovery and manufacturing, will lead its business development efforts going forward, the company said.
"We thank Chen for his contributions, particularly the roles he played as we established our collaborations with Amgen, GlaxoSmithKline and the Cystic Fibrosis Foundation," said Elkan Gamzu, PhD, interim CEO of Epix. "While Sheila will continue to transition into her expanded role, to date she has already led many Vasovist-related activities, including the worldwide technology transfer of rights to Epix as well as activities in support of our efforts to monetize Vasovist."
The Lexington, Mass.-based Epix said that DeWitt joined the management team of Epix in 2005 as the VP of business development and strategic planning and transitioned to the role of VP of discovery and manufacturing in 2007. As VP of business development and strategic planning, DeWitt played an integral role in the merger with Predix Pharmaceuticals.
Previously, DeWitt served in a variety of other R&D and business development roles including, vice president portfolio development and business unit head for strategic alliances and discovery at ArQule, business unit head for Chip-Based Discovery at Orchid Biosciences, founder and VP for Diversomer Technologies and a variety of scientific positions at Parke-Davis (now Pfizer).